Nostrum Laboratories Inc. ("Nostrum"), a wholly-owned subsidiary of Nostrum Pharmaceuticals, LLC announced today that it has acquired certain assets from a wholly-owned subsidiary of
Industries Ltd. ("Sun Pharma"), including its liquids and semi-solids manufacturing facility in
, related products and the unit's employees. Nostrum also acquired additional products from Sun Pharma's wholly-owned subsidiaries, which products will be manufactured for Nostrum under separate agreement. Sun Pharma will transition all sales and marketing responsibilities for the aforementioned products to Nostrum. Terms of the transaction were not disclosed.
Also read:
Sun Pharma sells one of its plants in the USIn connection with the transaction, Nostrum purchased the facility in
Bryan where Nostrum will manufacture the related products which it acquired from Sun Pharma and plans to develop and commercialize products there in conjunction with its manufacturing facilities in
Kansas City, Missouri and its affiliate's
research and development center in
Mumbai, India.
Commenting on the asset purchase Nostrum Chairman and CEO
Nirmal Mulye, Ph.D. said "We are pleased to complete this transaction with Sun Pharma and believe this acquisition strengthens our revenue base and ensures that we fulfill our organic growth initiatives."
Sun Pharma's CEO for N. America,
Kal Sundaram, added, "This transaction is a winning proposition for all parties as Nostrum Labs will continue to grow the
Bryan facility through the introduction of new products, thus ensuring the continued employment of the employees at
Bryan. Further, Sun Pharma will benefit from the collaboration with Nostrum Labs on product development opportunities in the future."
Nostrum and its parent are engaged in the formulation and commercialization of specialty pharmaceutical products and controlled-release, orally-administered, branded and generic drugs. Pharmaceutical companies are increasingly utilizing controlled-release drug delivery technologies to improve therapy. These technologies allow for the development of "patient-friendly" dosage forms, which reduce frequency of drug administration, thus improving patient compliance. Controlled-release pharmaceuticals can be especially beneficial for certain patient populations, such as the elderly, who often require several medications with differing dosing regimens. Nostrum has a rich portfolio of filed Intellectual Property. Nostrum's rich portfolio is supported by research and development in
Indiathrough its affiliate, Enem Nostrum Remedies Pvt. Ltd.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.